Company News

  • Reset
GOLDEN, Colo. — Feb. 20, 2018 — PharmaJet®, the maker of innovative, needle-free injection technology, today announced a global license agreement with Genexine, a leading biotherapeutics company headquartered in South Korea, for the development and commercialization of DNA vaccines for human applications using the PharmaJet needle-free injection systems.
View
GOLDEN, Colo. — Feb. 6, 2018 — PharmaJet, the maker of innovative, needle-free injection technology, today announced that Vaccibody AS is expanding their human clinical trial (phase IIa) for the study of a vaccine to treat HPV disease using the PharmaJet Stratis® needle-free injection system.
View
GOLDEN, Colo. — Jan. 23, 2018 — PharmaJet® Inc., the maker of innovative, needle-free injection technology, announced that a study was published in Heliyon Journal showing PharmaJet needle-free injection is superior to needle and syringe for fractional dose poliovirus vaccine campaigns.
Tags: Polio, Tropis
View
GOLDEN, Colo. — Jan. 9, 2018 — PharmaJet, the maker of innovative, needle-free injection technology announced that a recently published study in The Lancet demonstrated that delivery of a Zika virus vaccine with the PharmaJet Stratis® Needle-free Jet injector produced a significantly higher immune response, as compared with administration via
View
Menu